NCT02640404View on ClinicalTrials.gov

Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam

PHASE2CompletedINTERVENTIONAL

Enrollment

224

Participants

Timeline

Start Date

June 6, 2016

Primary Completion Date

December 5, 2016

Study Completion Date

December 5, 2016

Conditions

MeningitisMeningococcal MeningitisMeningococcal Infections

Interventions

BIOLOGICAL

Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

0.5 mL, Intramuscular. 2 doses 3 months apart

BIOLOGICAL

Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

0.5 mL, Intramuscular.

Trial Locations (1)

Unknown

Vĩnh Long

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02640404 - Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam | Biotech Hunter | Biotech Hunter